Management of HIV-Associated Thrombotic Thrombocytopenic Purpura
Treat HIV-associated TTP with immediate therapeutic plasma exchange (TPE), corticosteroids, rituximab, and caplacizumab (if available), while simultaneously initiating antiretroviral therapy (ART), following the same aggressive approach used for immune-mediated TTP in HIV-negative patients 1, 2.
Critical Distinction: Two Different Entities
HIV-associated thrombotic microangiopathy encompasses two distinct conditions that require different management:
HIV-Associated TTP (Severe ADAMTS13 Deficiency)
- ADAMTS13 activity <10% with or without detectable autoantibodies
- Occurs in patients with moderate immunosuppression (median CD4 ~151 cells/mm³)
- Sudden onset presentation
- Fewer opportunistic infections
- Responds to standard TTP treatment 3, 4
HIV-Associated TMA (Normal/Near-Normal ADAMTS13)
- Detectable ADAMTS13 activity
- Occurs in profoundly immunocompromised patients
- Progressive onset with multiple opportunistic diseases
- Poor response to TPE, worse prognosis
- May respond better to plasma infusion 3
Immediate Treatment Algorithm for HIV-Associated TTP
1. Initiate TPE Immediately Upon Clinical Suspicion
- Do not wait for ADAMTS13 results to start treatment 2
- Daily TPE sessions using plasma as replacement fluid (FFP is associated with increased mortality risk; HR 3.96, p=0.003) 4
- Continue until platelet count >150×10⁹/L and LDH <1.5× upper limit of normal 2
- Mortality drops from 15.7% to 3.9% with TPE 5
2. Concurrent Immunosuppression
- Corticosteroids: Methylprednisolone 1-2 mg/kg/day (higher doses for severe cases) 2
- Rituximab: 375 mg/m² weekly for 4 weeks
3. Caplacizumab (If Available)
- 10 mg/day (IV loading, then subcutaneous) 2
- Start upon ADAMTS13 confirmation (<10% activity)
- Continue until ADAMTS13 recovery
- Number-needed-to-treat = 35 to prevent one death 2
- Main risk: bleeding (rarely severe, treatable with VWF concentrate)
4. Antiretroviral Therapy (ART)
- Initiate ART promptly, even with normal CD4 counts 6
- High viral load (median 117,500 copies/mL) is typical at presentation 4
- Case reports show remission achieved with ART alone after ADAMTS13 relapse 7
- Do not delay ART - it addresses the underlying trigger 6
Critical Pitfalls and Monitoring
High-Risk Complications
- Sepsis complicates 16.3% of TPE courses and contributes to 20.7% of deaths 4
- Risk increases with TPE duration (OR 1.21 per session, p=0.002) 4
- Neurological deficits are the most common presentation (54.1%) 4
- Overall mortality remains 49% despite TPE, but drops to 2.2% with complete standard therapy 5, 4
When to Escalate
If patient fails to respond to plasma infusion within 24-48 hours:
- Escalate immediately to TPE - delays increase risk of seizures and death 8
- Patients with less advanced HIV disease behave like idiopathic TTP and require aggressive TPE 8
Prognostic Factors
- Better renal function reduces mortality (HR 0.97, p<0.001) 4
- Patients with moderate (vs. profound) immunosuppression have better outcomes 3
- Response rates comparable to HIV-negative TTP when treated aggressively 3
Follow-Up Management
- Monitor ADAMTS13 activity regularly after remission 2
- ADAMTS13 relapse (activity <20%) indicates high risk of clinical relapse even without symptoms 2
- Residual renal dysfunction is relatively rare in survivors 4
- Continue ART indefinitely to prevent TTP recurrence
The key principle: HIV-associated TTP with severe ADAMTS13 deficiency should be treated as aggressively as idiopathic TTP, with the critical addition of prompt ART initiation 1, 2, 3.